
Holds a PhD in Molecular Pharmacology and Cancer Therapeutics from SUNY Buffalo and Roswell Park Cancer Institute, where his research focused on drug resistance, cancer metastasis and the biology of cancer stem cells, the same stem-like cell population NSP's scoring is built around. Built the Neoantigen Selection Platform. Also, Partner, Business Development at Launchit Solutions.

Justin Leushner brings over 25 years of experience in molecular diagnostics, biotechnology, venture capital, and healthcare commercialization. Early in his career, he helped establish a national molecular diagnostics program at MDS Diagnostics, developing a strong foundation in genomics and molecular medicine. He subsequently served as an investment analyst with Canadian Medical Discoveries Fund, evaluating emerging biotechnology companies and investment opportunities. Justin co-founded Sernova Corp (TSX-SVA), a publicly traded biotechnology company focused on cell therapy and regenerative medicine, and held leadership roles at London Health Sciences Centre, advancing healthcare innovation and technology commercialization. His career also includes senior positions at TechAlliance and Clarivate, supporting emerging life sciences companies and advising organizations across the global pharmaceutical and healthcare sectors. He currently serves as Chief Business Officer at Launchit Solutions and Partner at Launchit Ventures, focusing on healthcare innovation, strategic partnerships, and biotechnology commercialization. Justin holds a B.Sc. in Cell Physiology and Genetics from the University of British Columbia, an MBA from Western University's Ivey Business School, and a number of technical designations in Forensic Science and Molecular Biology.
At the technology level, the company explicitly tests and improves model performance across a broader range of HLA types, because today's published neoantigen prediction models are trained on data skewed toward alleles common in European ancestry populations, a gap that matters for Canada's genetically diverse patient population. At the team level, this is an early, ongoing commitment rather than an established track record.